Rivogenlecleucel by Bellicum Pharmaceuticals for Sickle Cell Disease: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rivogenlecleucel overview
Rivogenlecleucel (BPX-501) is under development for the treatment of hematopoietic stem cell transplantation. It is administered through intravenous route. BPX-501 is a caspaCIDe candidate designed as an adjunct polyclonal donor T cell therapy administered after allogeneic HSCT. Donor T lymphocytes are transduced with a retroviral vector containing inducible caspase 9 and truncated CD19. It was also under development for the treatment of acute lymphocytic leukemia, acute myelocytic leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, unspecified hematological disorders, aplastic anemia, osteopetrosis, beta thalassemia, sickle cell disease, diamond-Blackfan anemia (congenital hypoplastic anemia), cytopenia and Fanconi anemia.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Bellicum Pharmaceuticals overview
Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical-stage biopharmaceutical company, that develops cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the areas of cellular immunotherapy including hematopoietic stem cell transplantation, CAR T cell therapy and TCR cell therapies. Its GoCAR™ technology builts a enhance effector cell proliferation and functional persistence and is designed to enlist wider immune cell engagement to target resistant tumor cells. Bellicum’s lead pipeline candidate includes BPX-501, an adjunct T-cell therapy intended for the treatment of leukemias, lymphomas and genetic blood diseases. The company also develops pipeline products for the treatment of solid tumors, hematological cancers and others. Bellicum is headquartered in Houston, Texas, the US.
For a complete picture of Rivogenlecleucel’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#Rivogenlecleucel #Bellicum #Pharmaceuticals #Sickle #Cell #Disease #Likelihood #Approval
